To explore these possibilities, we constructed a unique estrogen-negative mammary carcinoma mouse model in which tumor cell clones expressing high vs. low preset levels of Myc are tested for tumorigenic efficacy, separately and together, using a combination of experiment and in silico executable modeling of the intracellular oncogenic signaling network. This evidence concerns the gene MYC and neoplasm.